<DOC>
	<DOCNO>NCT01062659</DOCNO>
	<brief_summary>In order persist liver , HCV numerous nonspecific specific strategy overcome immunity host . The crucial step establishment viral persistence chronic hepatitis avoidance specific antiviral cellular immune response liver . Treatment pegylated interferon alpha ( IFNα ) combination ribavirin ( RBV ) standard therapy chronic hepatitis C . The response IFNα / RBV therapy depend effective cellular antiviral immune response liver . The understanding interaction HCV cellular immune response important effective use exist diagnostic technique , Individual control adjustment current therapeutic approach development future therapeutic immunization strategy . In study , investigator want investigate cellular Immune response liver HCV infect patient characterize influence immune response response IFNα / RBV therapy .</brief_summary>
	<brief_title>Cellular Immune Responses Liver Chronic Hepatitis C ( CHC ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>proven chronic hepatitis C age 18 65 willingness give write informed consent study protocol history receive IFN , PEGIFN RBV eligible antiviral treatment peginterferon ribavirin standard care</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>HCV</keyword>
	<keyword>hepatitis C virus</keyword>
	<keyword>CHC</keyword>
	<keyword>chronic hepatitis c</keyword>
	<keyword>interferon</keyword>
	<keyword>ribavirin</keyword>
	<keyword>Hepatitis , Viral , Human</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>peginterferon alfa-2a</keyword>
	<keyword>peginterferon alfa-2b</keyword>
</DOC>